v3.24.0.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues $ 9,835.6 $ 10,173.4 $ 10,981.7
Cost and expense:      
Cost of sales, excluding amortization and impairment of acquired intangible assets 2,533.4 2,278.3 2,109.7
Research and development 2,462.0 2,231.1 2,501.2
Selling, general and administrative 2,549.7 2,403.6 2,674.3
Amortization and impairment of acquired intangible assets 240.6 365.9 881.3
Collaboration profit sharing/(loss reimbursement) 218.8 (7.4) 7.2
(Gain) loss on fair value remeasurement of contingent consideration 0.0 (209.1) (50.7)
Acquired in-process research and development 0.0 0.0 18.0
Restructuring charges 218.8 131.1 0.0
Gain on sale of building 0.0 (503.7) 0.0
Other (income) expense, net 315.5 (108.2) 1,095.5
Total cost and expense 8,538.8 6,581.6 9,236.5
Income before income tax (benefit) expense and equity in loss of investee, net of tax 1,296.8 3,591.8 1,745.2
Income tax (benefit) expense 135.3 632.8 52.5
Equity in (income) loss of investee, net of tax 0.0 (2.6) (34.9)
Net income 1,161.5 2,961.6 1,727.6
Net income (loss) attributable to noncontrolling interests, net of tax 0.4 (85.3) 171.5
Net income attributable to Biogen Inc. $ 1,161.1 $ 3,046.9 $ 1,556.1
Net income per share:      
Basic earnings per share attributable to Biogen Inc. (in dollars per share) $ 8.02 $ 20.96 $ 10.44
Diluted earnings per share attributable to Biogen Inc. (in dollars per share) $ 7.97 $ 20.87 $ 10.40
Weighted-average shares used in calculating:      
Weighted average number of common shares outstanding (in shares) 144,700 145,300 149,100
Diluted earnings per share attributable to Biogen Inc. (in shares) 145,600 146,000 149,600
Product revenue, net      
Revenues $ 7,246.7 $ 7,987.8 $ 8,846.9
Revenue from anti-CD20 therapeutic programs      
Revenues 1,689.6 1,700.5 1,658.5
Contract manufacturing, royalty and other revenue      
Revenues $ 899.3 $ 485.1 $ 476.3